OPKO Health, Inc. (NASDAQ:OPK) Short Interest Down 16.6% in April

OPKO Health, Inc. (NASDAQ:OPK) was the target of a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 78,030,000 shares, a decline of 16.6% from the March 31st total of 93,610,000 shares. Based on an average daily trading volume, of 9,110,000 shares, the short-interest ratio is currently 8.6 days. Currently, 23.8% of the company’s stock are short sold.

OPKO Health Trading Up 3.3 %

OPK opened at $1.26 on Friday. The company’s 50 day moving average is $1.10 and its 200-day moving average is $1.23. The company has a current ratio of 1.55, a quick ratio of 1.22 and a debt-to-equity ratio of 0.15. OPKO Health has a 1-year low of $0.85 and a 1-year high of $2.24. The company has a market cap of $878.21 million, a P/E ratio of -5.04 and a beta of 1.82.

OPKO Health (NASDAQ:OPK) last released its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.09). OPKO Health had a negative net margin of 21.76% and a negative return on equity of 12.69%. The firm had revenue of $181.90 million during the quarter, compared to analyst estimates of $177.53 million. During the same quarter last year, the business earned ($0.11) EPS. The company’s revenue was down 1.9% compared to the same quarter last year. Equities research analysts predict that OPKO Health will post -0.33 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Phillip Md Et Al Frost bought 500,000 shares of the stock in a transaction that occurred on Monday, March 18th. The shares were acquired at an average cost of $0.87 per share, for a total transaction of $435,000.00. Following the completion of the acquisition, the chief executive officer now owns 210,968,225 shares in the company, valued at $183,542,355.75. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Richard M. Krasno bought 30,000 shares of the stock in a transaction that occurred on Monday, January 29th. The shares were acquired at an average cost of $0.99 per share, for a total transaction of $29,700.00. Following the completion of the acquisition, the director now owns 103,333 shares in the company, valued at $102,299.67. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Phillip Md Et Al Frost bought 500,000 shares of the stock in a transaction that occurred on Monday, March 18th. The shares were purchased at an average price of $0.87 per share, for a total transaction of $435,000.00. Following the completion of the acquisition, the chief executive officer now owns 210,968,225 shares of the company’s stock, valued at approximately $183,542,355.75. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 4,630,000 shares of company stock worth $4,422,700. Insiders own 47.26% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. IPG Investment Advisors LLC bought a new stake in shares of OPKO Health in the 4th quarter valued at $30,000. SlateStone Wealth LLC bought a new stake in shares of OPKO Health in the 1st quarter valued at $31,000. River Wealth Advisors LLC bought a new stake in OPKO Health during the 3rd quarter valued at $38,000. Moseley Investment Management Inc. bought a new stake in OPKO Health during the 1st quarter valued at $41,000. Finally, Northstar Group Inc. purchased a new position in OPKO Health during the 4th quarter worth $42,000. Institutional investors own 64.63% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a research report on Wednesday, April 3rd. Piper Sandler reaffirmed an “overweight” rating and set a $5.00 price target on shares of OPKO Health in a research report on Monday, April 1st. StockNews.com lowered shares of OPKO Health from a “hold” rating to a “sell” rating in a research report on Friday, March 1st. Finally, Barrington Research reiterated an “outperform” rating and set a $1.50 price objective on shares of OPKO Health in a research note on Monday, April 1st.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.